Coherus Oncology (CHRS) Cash from Investing Activities (2013 - 2026)

Coherus Oncology has reported Cash from Investing Activities for 14 years, with the latest figure at $30.7 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 275.31% year-over-year to $30.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $423.2 million (up 4102.03% YoY) and the FY2025 annual result came in at $375.1 million, up 62.85% from the prior year.
• Cash from Investing Activities advanced to $30.7 million in Q1 2026 per CHRS's latest filing, from -$2.8 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $462.6 million in Q2 2025 and troughed at -$129.9 million in Q4 2022.
• A 5-year average of $36.1 million and a median of $444000.0 in 2024 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities jumped 11160.39% in 2023, then tumbled 15241.22% in 2025.
• Over 5 years, Cash from Investing Activities stood at -$129.9 million in 2022, then jumped by 127.1% to $35.2 million in 2023, then sank by 101.54% to -$542000.0 in 2024, then sank by 423.62% to -$2.8 million in 2025, then surged by 1180.16% to $30.7 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $30.7 million, -$2.8 million, and -$67.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.